Condition: Neuroblastoma, Recurrent, Refractory · Neuroblastoma (NB) · Neuroblastoma in Children · Sponsor: Marzieh Ebrahimi
The goal of this clinical trial is to assess safety and efficacy of systemic injection of allogenic NK cells in patients with refractory/recurrent high-risk neuroblastoma. Is the injection of allogenic nk cells safe in patients with R/R high-risk neuroblastoma? Is the injection of allogenic nk cells effective in patients with R/R high-risk neuroblastoma? We will compare the NK cell administration group with a control group that receives conventional treatment to determine whether the intervention is safe and effective
This description comes directly from the study's public registry record.
Dr. Marzieh Ebrahimi · +98 9123448359 · m.ebrahimi@royan-rc.ac.ir
Always discuss trial participation with your own doctor first.
| Rasoul Akram Hospital | Tehran, Iran | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06674265